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Tumor-specific antigens have been demonstrated in several types of experimentally 
induced  tumors  by the  use  of various methods.  Many of these  antigens  have  the 
characteristics  of transplantation  antigens  (1).  Thus,  it is  possible  in  experimental 
systems to build up a specific transplantation  resistance against isografting of chemi- 
cally or physically induced tumors as well as against neoplasms of viral origin.  In the 
case of viral tumors, infection with polyoma,  SV40,  Gross,  Graffi, and Moloney leu- 
kemia viruses and adenovirns 12 has been found to induce a specific resistance (VIR) 
against subsequent isografting of tumor cells induced by the virus in question (2-14). 
This resistance might be an effect of the antiviral  immune response killing  all cells 
carrying the virus capsid  antigens.  However, experiments  with polyoma and  SV40 
tumors as  well  as  Shope papillomas  have  demonstrated  that  these  tumors possess 
specific cellular antigens which are not identical with the antigens of the mature virus 
particle  (15-17).  Therefore,  where  virus-infected  animals  are  concerned one has  to 
consider not only the possibility of an antiviral immune response but also an immune 
reaction against virns-induced cellular antigens. 
Tumors induced by the Schmidt-Ruppin variant of Rous sarcoma virus (RSV-SR) 
also possess specific antigen(s) detectable in transplantation tests (18) and by comple- 
ment-fixation tests as well (19, 20). These tumors appear to offer an especially interest- 
ing system for antigenieity studies. The mouse tumors induced by this RNA virus do 
not appear to release any infectious virus in vivo or in vitro but still  contain the virus 
genome. This can be detected in vivo by inoculation into chickens (21) or in vitro as a 
transformation  of chicken fibroblasts in mixed  cultures  of the tumor cells  and  sus- 
ceptible chicken cells  (22).  Of course, the possible  existence of helper virus must be 
considered in this connection (23). 
The present paper describes further and more detailed studies on the specific 
antigen(s)  of Rous sarcoma of mice detectable in transplantation  tests. 
Material and Methods 
M/ce.--The inbred strain A/Sn and its coisogenic  resistant sublines A.CA, A.BY, and A.SW 
as well as C57B1/K1 and different F1 hybrids between these strains and C3I-I/K1, C57L, and 
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CBA were used. The breeding and maintenance of these animals have been described previ- 
ously (2). 
The animals were kept in a unit also used for polyoma tumor experiments and they might 
therefore be contaminated by polyoma virus. Some of the mice used in the present experiments 
actually had positive titers of antipolyoma HI antibodies (up to  1/30720). To exclude the 
possibility that this polyoma contamination might interfere with  the transplantability of 
Rous tumors, several experiments included polyoma virus-inoculated recipients and uncon- 
taminated controls. No  difference was found between polyoma-infected mice and controls 
with regard to the frequency of takes or rate of growth of the Rous tumors. 
Virus.--A crude virus suspension was prepared using a  simplification of the method de- 
scribed by Bryan e¢ a/. (24). Rous chicken sarcomas induced by RSV-SR were suspended in 0.1 
potassium citrate solution and homogenized in a Waring blendor. After magnetic stirring for 
1 hour at -[-37°C and overnight at +4°C the preparation was centrifuged in an MSE cold cen- 
trifuge at 2000 RPM and the sediment discarded. Virus pools containing 2 to 10 X  104 focus- 
forming units (FFU)/ml were kept at  --65°C.  The titer remained constant during several 
months' preservation. 
Turnors.mSarcomas were induced in the strains A/Sn, A.CA,  A.BY,  C57B1/K1,  as well as 
in the A X  DBA andA X  C57B1 F1 hybrids by inoculating a suspension of living Rous chicken 
sarcoma cells (induced by RSV-SR). Tumors developed at the site of inoculation after 16 to 70 
days and showed the same histological picture as described earlier (21).  The neoplasms were 
transplantable in genetically compatible mice by mechanically prepared crude cell suspensions 
or trypsinized cells.  Mter 2 to 23 passages in mice, intramuscular inoculation of cell suspen- 
sions into chickens gave rise to characteristic Rous sarcomas. Transplantation tests with Rous 
sarcomas were performed with trypsinized cell suspensions. A known number of trypan blue 
unstained tumor cells (25) were inoculated subcutaneously into the flank of genetically com- 
patible recipients. In preliminary experiments the minimal cell doses required for progressive 
tumor growth in 100 per cent of untreated genetically compatible controls (= Din)  and in 
100 per cent of similar mice preirradiated with 400 r  total body irradiation (=Dmx)  were 
determined for each tumor. Dm varied between i02 and 5  X  104 cells and Dmx between 102 
and 5  X  108 for the 9 different tumors used. The recipients consisted of groups of mice pre- 
treated with 2 to 8 subcutaneous inoculations of mechanically prepared cell suspensions of (a) 
allogeneic Rous sarcomas and (b) allogeneic non-Rous control tumors derived from the same 
foreign mouse strain as the Rous sarcomas.  The last allograft was given 5  to  7  days before 
the challenge isograft. The control non-Rous  tumors included  2  "spontaneous"  mammary 
carcinomas, 2  methylcholanthrene-induced sarcomas, and 3  polyoma tumors.  Some experi- 
ments included animals pretreated with heavily irradiated  (8000 r)  syngeneic or allogeneic 
Rous tumor cells. 
Other types of recipient mice were inoculated 2 to 6 times intraperitoneally with 0.1 cc of 
the virus pool at adult age with the last injection being given  5 to 8 days prior to the test. 
Finally,  some  experiments included recipient mice,  pretreated with xenografts  of  Rous 
chicken sarcoma (induced by the Schmidt-Ruppin and Mill Hill virus strain, respectlvely). 
Mechanically prepared cell suspensions were inoculated subcutaneously 4 times at fortnight 
intervals. The first suspension was given in Freund's complete adjuvant. Control animals were 
inoculated with  suspensions  of  normal  chicken  tissues  derived  from  the  tumor-bearing 
animal. 
Chicken Antiserum.--Immunization  of chicken against RSV-SR was performed according 
to the method of Fink and Rauscher (26) using either formalin-killed or heated virus. Sera were 
collected from birds subsequently challenged with live virus and carrying regressing or slowly 
growing tumors. Sera from several birds were pooled and stored at -- 20°C. 
Mouse Serum was obtained from blood collected by puncturing the retroorbital sinus with a 
glass capillary. 
Virus Assay.--The  technique of Temin and Rubin  (27)  and Rubin  (28)  was used with NILS JONSSON AND HANS O. SJ6GREN  405 
slight modifications. About 90 per cent of the White Leghorn chicken embryos were uniformly 
susceptible to RSV-SR. Primary cultures were prepared in 200  ml serum bottles. Chicken 
serum was omitted from the medium and replaced by calf serum. The secondary cultures were 
infected on the day of seeding on plastic Petri dishes by adding 0.1 ml of each virus dilution. 
Foci were counted after Giemsa staining. 
Anfiviral antibodies were assayed according to the technique of Rubin eta/. (28, 29). After 
inactivation at 56°C for 30 minutes serum dilutions of 1:2 to 1:5 and 1:25 were incubated for 
30 minutes at 37°C with an appropriate virus dilution,  (giving 100 to 200 foci per dish in the 
absence of serum). At least 4 dishes were seeded for each virus-serum mixture. Every  test 
included chicken immune serum as a positive control. A 90 per cent reduction of the number of 
loci was regarded as specific neutralization. 
TABLE  I 
Results of 2 Transplantation  Tests with Tumor RYC (7th and 8lh Passages) 
Recipients 
Untreated controls 
Untreated controls 
AUografted with Rous 
tumors 
Allograffcd  with  Rous 
tumors 
Allografted  with  non-Rous 
tumors 
Anografted with non-Rous 
tumors 
iation* 
T 
4OO 
4OO 
40O 
No. of takes:~ after inoculation  of cell  number 
101 
6/13 
4/5 
O/1 
0/4 
4/4 
lO  s 
4/4 
4/4 
0/4 
t/4 
4/4 
4/4 
10  4 
4/4 
4/4 
0/4 
0/3 
m 
101 
0/4 
0/3 
2 X  10  i 
3/4 
2/4 
* 24 hours prior to test challenge. 
Figures denote fraction of mice with progressively growing tumors. The mice were ob- 
served for at least 90 days. 
Irradiation  Procedures.--Groups  of mice received total body x-ray irradiation in a dose  of 350 
or 400 r. For irradiation of tumor cells a dose of 8000 r was used. X-Rays were generated at 
200 kv, 15  ma, and faltered by 0.5 mm AI q- 0.5 mm Cu for the mice and by 1 mm A1 for 
the tumor cells. 
The test animals were inspected once a week for the appearance of tumors. Three diameters 
of the tumors were measured and the geometrical mean estimated. 
RESULTS 
Resistance against Isotransplantation after Pretreatment with Rous Tumor Allo- 
grafts.--Nine  different Rous  sarcomas  were transplanted to genetically com- 
patible recipients of the following 3 categories: untreated controls, mice pre- 
treated with Rous sarcoma allografts, and mice pretreated with allografts of 
non-Rous tumors. Several experiments were performed with each test tumor, 
as a rule including 3 different cell doses. Recipients were either unirradiated or 
x-irradiated 24 hours prior to test challenge. Several experiments included both 406  TRANSPLAIWTATION  ANTIGENS  IN ROUS  SARCOMA  OF MICE 
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28- 
24- 
~20- 
12- 
.= 
0 
6 
Test tumor RC57A 5th gen. 5xlO3¢eus 
o  o  NR 4/4 
• .......... "  R  3/4  /b  / 
..-'~ 
i  8  12  16  20  2~.  2~}  S2  36  4'0  4i  4'8 
Day= after inocutatlon 
lb  3~-  Teat tumor RG5"/A 5th gen. 5xlO4~t8 
o  o  U 4/4  ./~ 
28-  ="  .........  '  R 4/4  //~.~, ......  ~""/" 
24-  /  y/....,  ......................... 
i  16-~  P  ............ 
I~  " .O" 
:~  4  d 
0 
b  i  8  li  16  2b  2i  28  3?  3g  4b  4~,  4b  g2 
Days  cfter  inocutation 
FzGS.  1 a  and 1 b. Growth of 5 X  103 and 5 X  104 cells from fourth transfer generation of 
Rous tumor RCS7A after transplantation into preirradiated (400 r) syngeneic mice untreated 
(U)  or pretreated with allografts of the polyoma tumor SECX (NR) and the Rous tumor 
RCB (R), respectively. Figures denote fraction of mice with progressively growing tumors over 
total number inoculated. Each curve represents tumor growth in one recipient. 
unirradiated and irradiated recipients of the different categories. As an example, 
Table I summarizes the results of 2 experiments with 5 different inoculum doses 
of tumor RYC (induced in the A. BY strain). Recipients pretreated with Rous 
tumor allografts showed a strong resistance against the isografting of cell doses NILS JONSSON AND HANS  O.  SJOGREN  409 
ranging between 10  ~ and 105 cells. Not until 2 X  105 cells were inoculated was 
the resistance breaking down. Whole body x-irradiation with 400 r prior to the 
challenge did not abolish resistance. The recipients allografted with a non-Rous 
tumor  (a polyoma-induced osteogenic sarcoma)  had no demonstrable trans- 
plantation resistance against RYC. 
Table II summarizes the results of 28  tests with 6 tumors in unirradiated 
recipients. For each tumor the inoculum doses are given as multiples of the 
minimal cell number required for growth in all untreated controls (=Dm)  in 
preliminary tests. These pooled results clearly demonstrate  the  strong resist- 
ance of Rous tumor allograft pretreated recipients, when compared to untreated 
mice or animals pretreated with allografts of non-Rous origin. In mice pre- 
treated with allografts of non-Rous tumors a  weak transplantation resistance 
was sometimes expressed in a slightly reduced frequency of takes as compared 
to untreated controls. This weak resistance was not significant and could be 
completely abolished by irradiation. 
The pooled results of 28  tests with 9  different Rous tumors isografted to 
recipients x-irradiated 24 hours before test are presented in Table III. Dmx was 
found to be ~o to ~o of the Dm for thesame tumor except for the tumor RCB, 
for which Dmx was equal to 10  ~ cells= Dm. The transplantation resistance of 
Rous tumor allografted recipients was only slightly reduced as compared to the 
corresponding unirradiated animals. The weak resistance of the unirradiated 
non-Rous tumor allografted mice, however, was completely abolished by x-ir- 
radiation, and the frequency of takes was the same as in preirradiated controls. 
The difference between Rous tumor and the non-Rous tumor allografted ani- 
mals is highly significant. 
The resistance of the Rous tumor pretreated animals was manifested not only 
by a reduced frequency of takes but also by markedly prolonged latency periods 
and delayed tumor growth rate as compared to untreated controls or mice pre- 
treated with control tumors. This is demonstrated in Fig. 1, giving the growth 
curves of tumor RC57A with 2 different doses of inoculation. Although the 
frequency  of takesis 3/4 and 4/4 for 5 X  103 and 5 X  1@ cells, respectively, in the 
Rous allograft-pretreated group the tumors appear later and the rate of itumor 
growth is markedly reduced. The same results were regularly obtained also with 
the other tumors tested. Thus, the degree of resistance was higher than what is 
expressed by the rough take figures in the above tables. 
In order to prove the specificity of the isograft resistance further, 2 polyoma 
tumors were isografted to untreated controls, to mice previously allografted 
with polyoma tumor or Rous tumor and to polyoma virus-inoculated animals, 
respectively. Mice pretreated with polyoma virus or polyoma tumor showed 
the expected resistance, while no such resistance could be demonstrated in the 
Rous tumor allografted recipients. 
The tests for cross-reactivity between the different tumors used are sum- 
marized in Table IV. A clear-cut cross-resistance could be demonstrated be- 410  TRANSPLANTATION  ANTIGENS  IN ROUS  SARCOMA  0]~ MICE 
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tween Rous tumors, in all the combinations, while no cross-reactions were found 
between Rous tumors and polyoma tumors or various non-viral neoplasms. 
Isograft Resistance Induced by Hea~ly Irradiated Rous Tumor Cells or by Crude 
Fractions  of Ultrasonically Disrupted  Rous Sarcoma Cells.--Since x-irradiation 
has been shown to abolish the immunizing capacity of polyoma tumor cells (15) 
but not that of methylcholanthrene- and SV40-induced neoplasms (30,  31), it 
seemed desirable to investigate the effect of x-irradiation on the antigenicity of 
Rous tumor cells.  Table V summarizes the results. It is quite clear that the ir- 
radiated  (8000 r) Rous tumors are capable of inducing a clear-cut transplanta- 
TABLE  VI 
Results  of IsotransplantaHon  of  Tumor  RSC  (5  X  10  a Cells)  to  Recipients  Pretreated with 
Sonically Disrupted  or Heavily Irradiated Allogeneic Rous Tumor Cells. Recipients 
X-Irradiated  (400 r) 24 hours before Test 
Pretreatment 
Untreated controls .........................  I  4/5 
Supernatant~ .............................  1  1/4 
Sediment~ ................................  t  3/5 
HR-Rous tumor cells (8000r) ...............  l  0/5 
UnirradiatedRous  tumor ceHs  ..............  l  1/4 
Non-Rous tumor cells  ......................  t  -- 
No. of takes" 
Experiment 
2 
4/4 
4/S§ 
4/5 
3/5 
4/5§ 
5/5 
Expe3rlment 
5/5 
4/4§ 
4/4§ 
2/5 
Total 
13/14 
9/13 
n/14 
3/lO 
7/14 
5/5 
* Figures denote fraction of mice with progressively growing tumors. 
~t Ultrasonic  treatment  2  minutes  (ultrasonic  power  unit  MSE).  Centrifugation  4000 
~,  10 minutes. 
§ Means prolonged latency period and/or slower tumor growth than in control animals. 
tion resistance,  which  appears to be somewhat stronger  than in  the animals 
pretreated with non-irradiated Rous allografts. This might be due to the fact 
that the unirradiated cell suspension was diluted  1:10 in comparison with the 
irradiated suspension. This difference was introduced in an attempt to compen- 
sate for the multiplication of the non-irradiated cells prior to regression. Pre- 
treatment with non-Rous tumor allografts gave no resistance.  The results of 
pretreatment with heavily irradiated syngeneic or allogeneic Rous tumor cells 
are also included in Table IV. 
In order to investigate whether integrity of the whole celt is essential for im- 
munization, a  series of experiments was performed with ultrasound  disrupted 
cell fractions. After 2 minutes' sonication (ultrasonic power unit MSE, 18 to 20 
kc per sec.) the mechanically prepared cell suspension was centrifuged at 4000 
~p~a for 10 minutes. The upper half of the supernatant was cautiously removed. 
The sediment was resuspended in the rest of the supernatant.  Groups of mice NILS  JONSSON  AND  ttANS  O.  SJOGREN  413 
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pretreated  with  4  subcutaneous  inoculations  of the  supernatant  or sediment 
revealed  a  weak  but  clear-cut  transplantation  resistance  on  subsequent  iso- 
grafting of tumor RSC (Dmx given to the preirradiated recipients)  (Table VI). 
The resistance  was indicated  by a  slightly reduced  frequency of takes  and  a 
slower tumor growth than in untreated animals or mice pretreated with control 
tumor. It was weaker than the resistance induced by intact or lethally irradiated 
Rous tumor cells. 
Test  tumor  RDAA  8th  gen.  5xlO2¢ell$ 
o  o  U  4/4 
24  ~---=  MH  5/5 
•  ...........  SR  3/4  t~  =  =_.j ~ 
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Days after  inoculation 
Fzo. 2. Growth of 5 X  10  ~ cells from the seventh transfer generation of Rous tumor RDAA 
after transplantation  into preirradiated  (400 r) syngeneic mice, untreated  (U) or pretreated 
with xenografts of Rous chicken sarcoma, strain  Mill  Hill (MH), or Rous chicken sarcoma, 
strain  Schmidt-Ruppin  (SR). Figures  denote  fraction  of mice  with  progressively  growing 
tumors  over total number  inoculated. The tumor growth curve of the untreated  mice rep- 
resents  the  mean  volume  of all 4 tumors  (the open  circles giving the individual  values), 
while the curves of the xenografted animals represent the growth of individual tumors. 
Transplantation  Tests in Mice Pretreated with RSV-SR  Viru,  r Pool or Xeno- 
grafts of Rous Chicken Sarcoma.--In analogy with the virus-induced transplan- 
tation resistance (VIR) demonstrated for various virus-induced neoplasms  (2- 
14), attempts were made to induce isograft resistance against Rous tumors by 
pretreatment  with  RSV-SR-containing  materials.  Groups  of  mice were pre- 
treated  with  (a) 0.1 ml of the RSV-SR pool inoculated at least 4  times intra- 
peritoneally  every  second  week,  (b)  4  xenografts  of Rous  chicken  sarcomas 
induced by RSV-SR or the Mill Hill-Rous virus strain (RSV-MH), respectively, 
and as a negative control to these, (c) xenografts of normal chicken tissues. The 
results of Rous tumor isografting into these groups are presented in Table VII. 
At the Dm level, RSV-SR, chicken Rous sarcoma, and normal  chicken cells 
all appeared to induce an isograft resistance in comparison with untreated recip- NILS JONSSON AND  HANS  O.  SJOOREN  415 
ients, provided that none of the groups was irradiated. Whole body irradiation 
24 hours before challenge abolished the resistance induced by the RSV-SR pool 
and normal chicken cells,  and in most cases also that induced by Rous chicken 
sarcoma as shown in Table VII. Chicken sarcoma induced  by the RSV-MH 
induced no demonstrable resistance in irradiated animals. 
The experiment in which a  slight resistance was demonstrated in recipients 
pretreated with chicken Rous sarcoma xenografts is presented in Fig.  2.  The 
TABLE  VIII 
Titer of RSV-SR-Neutralizing  Antibodies  in Sera of Mice after Inoculation  of a  Virus Pool or 
Pretreatment  with Iso-, Allo-, or Xenografts  of Rous Sarcoma 
Pretreatment 
Untreated 
Iso-  or  allografted  with  Rous tumor 
Results of 
transplantation tests 
Resistant 
Non-resistant 
Xenografted  with  Rous  chicken sarcoma 
(when adult) 
Xenografted  with  Rous  chicken sarcoma 
(when new-born) 
Virus pool 
Resistant 
Non-resistant 
Resistant* 
Non-resistant 
Non-resistant 
No.  of tested  sera 
with  titer 
<1:3  1:3-1:5  ~1:20 
6  --  -- 
11  --  -- 
2  --  -- 
11  --  -- 
4  1  -- 
1  --  2 
*  The transplantation  results  have been published (32). 
resistance was complete in 1 animal while in the other 3 recipients it was ex- 
pressed as a  clearly diminished growth rate compared to untreated and MH- 
sarcoma xenografted mice. 
Tests for Virus-Neutralizing Antibodies in the Sera of Mice Used in the Trans- 
plantation  Tests.--The antiviral activity of sera obtained from mice exhibiting 
a  specific isograft immunity according to the transplantation  tests described 
above, was tested with the focus-neutralization technique of Rubin et al.  (28, 
29). Each test included 2 serum dilutions  (1:2,  1:3, or 1:5 and 1:20 or 1:25, 
respectively) and one chicken immune serum as a positive control. In order to 
exclude the possibility that mouse sera contained factors which inhibited virus- 
neutralization,  a  mixture of equal parts of normal mouse serum and chicken 
immune serum was tested. The mixture neutralized the virus as efficiently as the 
immune serum alone, 
The results of the neutralization tests are given in Table VIII. No virus-neu- 416  TRANSPLANTATION ANTIGENS  IN  ROUS  SARCOMA  OF  MICE 
tralizing activity was demonstrated in any of the animals, pretreated with RSV- 
SR or iso-, allo-, or xenografts of Rous tumors, no matter whether transplanta- 
tion resistance could be demonstrated or not. 
The neutralization tests also included sera from mice, inoculated with Rous 
chicken sarcoma material when newborn. Isograft resistance was demonstrable 
in animals not developing primary tumors (32). As shown in Table VIII, 2 of 
the 3 non-resistant mice tested had virus-neutralizing antibodies in a  titre of 
1:20, and one of the 5 tested sera from resistant mice neutralized in  dilution 
1:3 but not 1: 30. 
DISCUSSION 
The present investigation clearly demonstrates that Rous sarcomas in mice 
possess common specific transplantation antigen(s). In all combinations tested 
the Rous tumors cross-reacted while no cross-resistance was demonstrable be- 
tween Rous sarcomas and neoplasms induced by polyoma virus or of non-viral 
origin. All Rous sarcomas were capable to induce resistance and responded to 
the specific immunity induced  by other  Rous  tumors.  Non-Rous  neoplasms 
showed neither of these qualities. 
The controls included in the transplantation tests ruled out such non-specific 
effects as the stimulation of the immunological reactivity by allograft pretreat- 
ment. If this were the case, allografted mice would be expected to develop resist- 
ance against antigenic tumors of different origin, as well; this was not the case. 
Furthermore, allografting with non-Rous tumors derived from the same mouse 
strain as the Rous allografts did not induce resistance against Rous tumor iso- 
grafts. These controls also exclude the possibility that the specific anti-Rous 
isograft resistance was directed against isoantigens due to possible residual het- 
erozygosis in the animals used. Whole-body x-irradiation (400 r) of the isograft 
recipients 24 hours prior to challenge was another precaution introduced to rule 
out non-specific effects. This dose of irradiation is known to decrease subsequent 
primary immune responses markedly (33) while secondary responses are much 
less affected. Comparison between the results summarized in Tables II and III 
deafly shows that the isograft resistance of Rous tumor-aUografted mice is only 
somewhat reduced by x-irradiation and the specificity of this resistance is thus 
established  beyond doubt.  In  contrast,  the slight  resistance of unirradiated 
recipients pretreated with allografts of various non-Rous tumors is completely 
abolished by x-irradiation and can be best explained as a non-specific stimula- 
tion of the primary immune response. A similar non-specific isograft resistance 
against methylcholanthrene-induced mouse sarcomas is sometimes induced by 
tumorous or non-tumorous grafts (34). 
A  clear-cut transplantation immunity was induced not only by intact cells 
but by irreversibly x-ray damaged Rous sarcoma cells as well. The immunizing 
efficiency of irradiated cells has previously been demonstrated for chemically NILS  JONSSON  AND  HANS  0.  SJOGREN  417 
induced tumors and SV40 hamster sarcomas (30, 31),  while the polyoma cell 
antigen appeared to be radiosensitive (15). Irradiated Graffi leukemia cells in- 
duce specific isograft immunity (10) but in this case it is not known whether the 
resistance is induced by the cells themselves or by the virus that they always 
contain. The mouse Rous sarcomas do not release any detectable infectious 
virus in vivo or in vitro and therefore the immunity is most likely induced by 
radioresistant cellular antigen(s) peculiar to tumors induced by this agent. 
The presence of common tumor-specific transplantation antigen(s) in Rous 
sarcomas of mice is analogous to the existence of specific antigens in a number 
of other virus-induced tumors. The antigens are common for various tumors 
induced by the same virus but different for neoplasms induced by different vi- 
ruses. In most cases it is not known whether the antigens are identical with or 
different from viral antigens. However, in tumor systems where non-virus-re- 
leasing tumor cells are available, polyoma and SV40 tumors, it has been shown 
that specific  antigen(s) having a  specificity distinct from the complete virus 
antigen(s) are common for tumors induced by the same virus (15,  16). 
Infection of adult animals with oncogenic viruses has been found to induce 
an isograft resistance (VIR) specific against tumors induced by the same virus 
in question in all systems so far studied. In several cases attempts have been 
made to differentiate between an antiviral immune response inhibiting ceils 
carrying viral antigen(s) and an immune reaction directed against specific cellu- 
lar antigen(s) developing in virus-infected cells and in established virus-induced 
tumor cells. 
Attempts have been made to induce the VIR against Rous tumors by pre- 
treatment with a  RSV-SR virus pool or xenografts of virus-containing Rous 
chicken sarcoma assumed to release virus in the host animal. Unirradiated re- 
cipients pretreated with the virus pool showed only a weak resistance which was 
completely abolished by preirradiation and was thus probably non-specific. This 
resistance was of about the same order of magnitude as demonstrated in unir- 
radiated virus-pretreated hamsters (35). Although the virus pool used for pre- 
treatment had a relatively high titer the lack of immunization may be due to an 
insufficient antigen dose, since the Rous virus cannot multiply in adult mice or 
does so to a very limited extent only. The absence of an antiviral immune re- 
sponse in the form of virus-neutralizing antibodies (Table VIII) supports this 
explanation. 
Similarly, most mice xenografted with Rous chicken sarcoma tissue failed to 
develop any specific resistance (Table VII). Only one experiment (Fig. 2) re- 
vealed a weak resistance. No virus-neutralizing activity could be demonstrated 
in the sera of xenografted animals including those exhibiting the slight isograft 
resistance. 
The isograft immunity  demonstrated in the absence of antiviral antibodies in 
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plantation antigen(s) and viral antigen(s). However, such an identity cannot be 
excluded since humoral virus-neutralizing antibodies are not readily induced 
after virus infection of mice. Even if directed against  the same antigens  the 
development of a  transplantation  resistance must not necessarily be accom- 
panied by the development of humoral virus-neutralizing antibodies. Relevant 
in this connection are some recent transplantation tests in mice pretreated with 
Rous chicken sarcoma when newborn (32). The animals that failed to develop 
primary tumors within 6 weeks showed an isograft resistance, while recipients 
pretreated with the same chicken tumor material as adults showed only a very 
weak resistance as in the present study. As indicated in Table VIII it was found 
that  the resistant mice contained no detectable virus-neutralizing antibodies 
while 2 non-resistant mice did show positive fiters. Thus there seems to be no 
correlation between  the  antiviral  immune  response and  the  development of 
isograft resistance. This appears to be a  strong argument against the possible 
identity between the transplantation antigen(s) and viral antigen(s). The rea- 
son why newborn mice responded better than adults may be explained in vari- 
ous ways. Rous chicken sarcoma cells or the Rous virus may survive longer in 
newborns than in adults.  The newborns would be exposed to a  heavier virus 
infection affecting a larger number of mouse cells with subsequent induction of 
the specific antigen(s). The fact that adults do not respond well suggests that 
the resistance is not due to an immunization against antigen(s) fully expressed 
in the chicken sarcoma cells inoculated, since adult mice are more immunolo- 
gically competent than newborns. It would follow that the postulated specific 
antigen of mouse Rous sarcomas is not identical with that of chicken sarcomas. 
Another point favouring the non-identity of the tumor-specific antigen and 
virus antigen(s), is the finding that cell-free mouse Rous tumor extracts were 
capable of inducing isograft immunity. The extracts did not contain any in- 
fectious Rous virus according to the test performed in vitro and in vivo. Since 
no resistance was induced by similar extracts of Rous chicken sarcomas which 
certainly contain  relatively large amounts  of virus,  the  conclusion must  be 
drawn  that  the  resistance was most probably induced by cellular  antigen(s) 
present in the mouse tumor extract. 
The demonstration of specific antigen(s)  in mouse Rous  sarcoma extracts 
capable of inducing isograft resistance contrasts with the results of complement 
fixation tests (19, 20). The latter revealed specific common antigen(s) in cell- 
free extracts of sarcomas induced in hamsters and guinea pigs by RSV-SR and 
a corresponding antibody activity in tumor-bearing animals. The CF antigen(s) 
appeared to be identical with viral antigen(s) since sera obtained from tumorous 
animals reacted not only with extracts of Rous sarcomas induced in different 
species but also with pools of various related viruses such as myeloblastosis 
virus and lymphomatosis virus (R_IF). In order to obtain an integrated picture 
of the RSV-SR carcinogenesis, it appears to be necessary to clarify the relation- NILS JONSSON AND HANS 0. SJOGREN  419 
ship between the transplantation antigen(s), the CF  antigen(s),  and  the viral 
antigen(s) further. 
SUMMARy 
Mice allografted with different sarcomas, induced  by the  Schmidt-Ruppin 
variant of Rous sarcoma virus (RSV-SR), showed a  resistance against subse- 
quent isograffing of 9 different Rous sarcomas. Transplantation resistance could 
also be induced by Rous mouse tumor cells x-irradiated with 8000 r or with cell- 
free tumor extracts, containing no demonstrable virus. No transplantation re- 
sistance could be demonstrated after allograft pretreatment with various poly- 
oma  tumors  or  non-viral  tumors.  Allograft pretreatment  with  Rous  tumors 
induced no demonstrable resistance against isografting of polyoma tumors. In- 
oculation of RSV-SR or Rous chicken sarcoma suspension into adult mice gave 
no  clear cut  resistance  against isografting of mouse  sarcomas. Neither  after 
allografting of Rous tumors nor after virus or chicken sarcoma inoculation into 
adult mice could virus-neutralizing activity be demonstrated in the sera. 
The results demonstrate  the presence of common, specific transplantation 
antigen(s) in different Rous sarcomas in mice and speak against an identity be- 
tween the transplantation antigen(s) and viral antigen(s). 
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